At the news
? MIXEDIMPACT 7/10 S-4 filed Jul 20, 2026 at 06:45 ET
Standard Biotools (LAB) files S-4 for its all-stock merger with private biotech Treeline Biosciences, valuing Treeline at $2.5B and LAB at $460M. LAB shareholders will own ~16% of the combined company, which will focus on Treeline's clinical-stage oncology pipeline with ~$1.06B in pro forma cash. The filing also includes a CVR tied to monetization of LAB's legacy businesses, up to 76M shares. The merger requires LAB shareholder approval and is expected to close in H2 2026.
- Treeline valued at $2.5B, LAB at $460M; combined pro forma cash ~$1.06B
- LAB shareholders to own ~16% of combined company on a fully diluted basis
- Treeline has three Phase 1 programs (TLN-121, TLN-254, TLN-372) and a fourth nearing clinical entry (TLN-499)
- TLN-254 (EZH2 inhibitor) under partial clinical hold due to class-wide safety concerns with tazemetostat
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access